



Low Birth Weight Is a Risk Factor for Severe Retinopathy of Prematurity Depending on Gestational Age

Pia Lundgren^{1*}, Anna Kistner^{1,2}, Eva M. Andersson³, Ingrid Hansen Pupp⁴, Gerd Holmström⁵, David Ley⁴, Aimon Niklasson⁶, Lois E. H. Smith⁷, Carolyn Wu⁷, Ann Hellström^{1¶}, Chatarina Löfqvist^{1¶}

1 Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, **2** Institution of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, **3** Department of Occupational and Environmental Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, **4** Department of Pediatrics, Institute of Clinical Sciences, Lund University and Skane University Hospital, Lund, Sweden, **5** Department of Neuroscience, Ophthalmology, Uppsala University, Uppsala, Sweden, **6** Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, **7** Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Objective: To evaluate the impact of low birth weight as a risk factor for retinopathy of prematurity (ROP) that will require treatment in correlation with gestational age at birth (GA).

Study design: In total, 2941 infants born <32 weeks GA were eligible from five cohorts of preterm infants previously collected for analysis in WINROP (Weight IGF-I Neonatal ROP) from the following locations: Sweden (EXPRESS) ($n = 426$), North America ($n = 1772$), Boston ($n = 338$), Lund ($n = 52$), and Gothenburg ($n = 353$). Data regarding GA at birth, birth weight (BW), gender, and need for ROP treatment were retrieved. Birth weight standard deviation scores (BWSDS) were calculated with Swedish as well as Canadian reference models. Small for gestational age (SGA) was defined as BWSDS less than -2.0 SDS using the Swedish reference and as BW below the 10th percentile using the Canadian reference charts.

Results: Univariate analysis showed that low GA ($p < 0.001$), low BW ($p < 0.001$), male gender ($p < 0.05$), low BWSDS_{Canada} ($p < 0.001$), and SGA_{Canada} ($p < 0.01$) were risk factors for ROP that will require treatment. In multivariable logistic regression analysis, low GA ($p < 0.0001$), male gender ($p < 0.01$ and $p < 0.05$), and an interaction term of BWSDS*GA group ($p < 0.001$), regardless of reference chart, were risk factors. Low BWSDS was less important as a risk factor in infants born at GA <26 weeks compared with infants born at GA ≥ 26 weeks calculated with both reference charts (BWSDS_{Sweden}, OR = 0.80 vs 0.56; and BWSDS_{Canada}, OR = 0.72 vs 0.41).

Conclusions: Low BWSDS as a risk factor for vision-threatening ROP is dependent on the infant's degree of immaturity. In more mature infants (GA ≥ 26 weeks), low BWSDS becomes a major risk factor for developing ROP that will require treatment. These results persist even when calculating BW deficit with different well-established approaches.

Citation: Lundgren P, Kistner A, Andersson EM, Hansen Pupp I, Holmström G, et al. (2014) Low Birth Weight Is a Risk Factor for Severe Retinopathy of Prematurity Depending on Gestational Age. PLoS ONE 9(10): e109460. doi:10.1371/journal.pone.0109460

Editor: Demetrios Vavvas, Massachusetts Eye & Ear Infirmary, Harvard Medical School, United States of America

Received: April 28, 2014; **Accepted:** September 4, 2014; **Published:** October 15, 2014

Copyright: © 2014 Lundgren et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

Funding: This work was supported by the Swedish Medical Research Council (grant numbers 2011-2432 and 2008-2842), government grants (grant numbers ALFGB-137491 and ALFGB-21611), VINNOVA (grant numbers 2009-01152 and 2009-00221), the Torsten and Ragnar Söderberg Foundation, the Skåne Council Foundation for Research and Development, the Linnéa and Josef Carlsson Foundation, and, in part, by the NIH/NEI (EY022275, EY017017, P01 HD18655), Research to Prevent Blindness Senior Investigator Award, Alcon Research Institute Award, Lowy Medical Foundation, Herman Svensson Foundation and V. Kann Rasmussen Foundation and European Commission FP7 project 305485 PREVENT-ROP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: pia.lundgren@gu.se

¶ These authors are last authors on this work.

Introduction

Retinopathy of prematurity (ROP) is a disease affecting very preterm infants that can potentially result in blindness. Timely detection and treatment of ROP is crucial. It is important to determine all risk factors in order to improve the identification of infants at greatest risk for severe ROP.

The most important risk factors for ROP are the degree of prematurity [1] and low birth weight (BW) [2], but there are other risk factors associated with infant postnatal morbidity such as days

of ventilation [3], sepsis [4], hyperglycemia [5], blood transfusions [6], and bronchopulmonary dysplasia [7].

In recent years, studies have consistently identified poor postnatal weight gain as a strong predictor of ROP [8–12]. Study findings have, however, been contradictory as to whether or not prenatal growth restriction is a risk factor for ROP. Prenatal growth restriction can be defined as the infant's deficit from normal birth weight standard deviation score (BWSDS). The term small for gestational age (SGA), defined as BW per GA below a certain percentile or confidence interval based on growth charts, is

also frequently used to describe infants' prenatal growth restriction. SGA was found to be a risk factor for ROP in some studies [2,13–15]. However, in other studies no significant differences were found between infants born SGA and those with a BW appropriate for their gestational age and the risk of developing ROP [3,16–18]. A possible explanation for these inconsistent results may be differences in the characteristics of the study populations and study designs. The definition of SGA has varied in previous studies where it has been defined as a BW ranging from below the 3rd (approximately corresponding to 2 SD below the gestational-age related mean) to below the 10th percentile. Furthermore, the definition of normal BW in relation to GA varies according to different growth charts. Growth charts used throughout the world vary in design; some are based on longitudinal fetal ultrasound weight estimations and thereby aim to reflect undisturbed intrauterine growth [19,20], some are based on live births [21,22], and others on live as well as still births [23].

Therefore, the aim of this study was to clarify the association between low BW and the development of ROP that will require treatment in a large cohort of very preterm infants. Calculation of BW deficit and definition of SGA was performed according to different reference models of GA-related growth to determine if this would affect the results.

Our major findings were that low BWSDS is a risk factor for preterm infants who will require treatment for ROP and that the impact of low BWSDS in more mature infants who will require ROP treatment is greater. The results persisted independent of differences in the growth charts applied.

Study Population and Methods

Study population

For this study, data from five cohorts enrolled in the WINROP (Weight IGF-1 Neonatal ROP) studies were retrospectively reviewed. These were: the *EXPRESS cohort*, extremely preterm (GA <27 weeks, $n = 707$) infants born in Sweden between 2004 and 2007 [24]; *North American multicenter cohort*, preterm infants ($n = 1965$) born at ten level III neonatal intensive care units in the USA and Canada between 2006 and 2009 [25]; *Boston cohort*, preterm infants ($n = 374$) born at Brigham and Women's Hospital, Boston (USA) between 2005 and 2008 [26]; *Lund cohort*, preterm infants ($n = 60$) born at Skane University Hospital, Lund (Sweden) between 2005 and 2007 [11]; and *Gothenburg cohort*, preterm infants ($n = 354$) screened and/or treated for ROP at Sahlgrenska University Hospital, Gothenburg (Sweden) between 2004 and 2007 [10]. Comprehensive descriptions of all infants and data collected in each cohort have been reported previously [10,11,24–26].

Data regarding correlations between ROP requiring treatment and GA, BW, and gender were retrieved retrospectively from each original study. In the current analysis, infants were excluded if they were born after 32 week GA. Infants who died before 40 weeks postmenstrual age were also excluded since ROP grading may have been incomplete. Due to different inclusion criteria in the cohorts, the number of infants excluded due to death before 40 weeks postmenstrual age differed. The number of infants excluded in each cohort is presented in Figure 1.

ROP screening and treatment

ROP screening examinations were conducted according to current national guidelines for each cohort. The revisited International Classification of Retinopathy of Prematurity was used for ROP classification in all cohorts [27]. Details on current ROP screening guidelines and schedules and the performance of

the ROP examinations are described in each previous publication [1,10,11,24–26]. The recommendations of the Early Treatment for Retinopathy of Prematurity Cooperative Group were followed for treatment [28].

Statistical analysis

Birth weight standard deviation scores (BWSDS) were calculated using two well-established growth charts, both developed for infants born after 22 weeks GA. The Swedish gender-specific reference is considered to reflect undisturbed intrauterine growth [19], and the Canadian gender-specific reference is based on live as well as still births [23]. SGA was defined as BW less than -2.0 BWSDS based on the Swedish growth reference and as BW below the 10th percentile based on the Canadian growth reference. We further defined severe growth restriction as a BW below the 3rd percentile using the Canadian growth reference.

The outcome indicator variable was whether or not the infants required ROP treatment. Logistic regression was used to analyze risk factors. Infants were divided into five GA week groups; infants born at GAs of 22–23 weeks, 24–25 weeks, 26–27 weeks, 28–29 weeks, and 30–31 weeks. For infants born GA ≥ 26 weeks, all variables reflecting prenatal growth restriction, regardless growth reference or definition, were highly significant as risk factors as follows: BWSDS_{Sweden} for GA 26–27 weeks and for GA 28–29 weeks (p -values <0.01); SGA_{Sweden} for GA 26–27 weeks ($p < 0.001$); BWSDS_{Canada} for GA 26–27 weeks and for GA 28–29 weeks (p -values <0.01); SGA_{Canada} for GA 26–27 weeks and for GA 28–29 weeks (p -values <0.01); severe growth restriction (Canada) for GA 26–27 weeks and for GA 28–29 weeks ($p < 0.001$). To assess whether BWSDS had a different impact on ROP requiring treatment for infants born at GA <26 weeks compared with infants born at GA ≥ 26 weeks, we allowed for different associations with BWSDS by including an interaction term (BWSDS*GA group, where GA group = 1 if GA ≥ 26 weeks and 0 if GA <26 weeks). The multivariable logistic regression analysis included GA, gender, BWSDS, the indicator variable GA group, and the interaction term BWSDS*GA group. Two different BWSDS were calculated; one using the Swedish growth reference and one using the Canadian growth reference. Hence, two multivariable logistic regression models were estimated.

IBM SPSS Statistics 20 for Microsoft Windows (IBM Corporation, Armonk, NY) was used for statistical analysis as well as SAS version 9.3. Mann-Whitney U test was used for group comparisons. Correlations were assessed using the Spearman correlation coefficient (r_s). Wilcoxon Signed Rank test was used to compare the two BWSDS references. The association with the outcome (ROP requiring treatment or no ROP treatment) is expressed as the odds ratios (OR) with 95% confidence intervals (CI). The Hosmer and Lemeshow test was used to assess the goodness-of-fit for the multivariable logistic regression model [29].


Ethics statement

The Swedish studies were approved by the Regional Ethical Review Board of Gothenburg, Sweden. The American studies were retrospective chart reviews; hence no consent for data retrieval was needed.

Results

Study population

For this study, 2941 infants were eligible. Infants were from the EXPRESS cohort (426 infants), North American cohort (1772 infants), Boston cohort (338 infants), Lund cohort (52 infants), and the Gothenburg cohort (353 infants) (Figure 1). The birth



Abbreviations: FEVR indicates familial exudative vitreoretinopathy; GA, gestational age; PMA, postmenstrual age; WINROP, weight IGF 1 neonatal retinopathy of prematurity.

*84 infants in the EXPRESS study were also included in the Lund and Gothenburg cohort; hence, these infants were excluded from the EXPRESS study.

Figure 1. Flowchart of the study population.
doi:10.1371/journal.pone.0109460.g001

characteristics of infants in each cohort/GA group are described in Table 1.

BWSDS and GA groups

A negative correlation between BWSDS and GA was found regardless of growth reference; low BWSDS was associated with higher GA (Swedish reference: $r_s = -0.25$, $p < 0.001$, Canadian reference $r_s = -0.12$, $p < 0.001$). Median BWSDS, regardless of definition, was lower in infants treated for ROP compared with infants not treated for ROP between GA 24–29 weeks (Mann-Whitney U test, $p < 0.05$, Figure 2).

Prevalence of SGA

The prevalence of SGA, regardless of definition, increased with GA. The prevalence of SGA_{Sweden} was 5.6% (7/126) in the 22–23 weeks GA group, and increased to 40.4% (289/716) in the 30–31 weeks GA group. The prevalence of SGA_{Canada} was 4.0% (5/126) in the 22–23 weeks GA group and increased to 17.6% (126/716) in the 30–31 weeks GA group (Table 1).

Prevalence of infants treated for ROP

The prevalence of infants treated for ROP was 45.2% (57/126) in the 22–23 weeks GA group. The prevalence decreased to 0.1% (1/716) in the 30–31 weeks GA group. The prevalence of infants treated for ROP varied from 17.1% (73/426) in the EXPRESS cohort to 4.1% (14/338) in the Boston cohort (Table 1).

Risk factors for ROP that will require treatment

Possible risk factors for an infant who will require ROP treatment were as follows: GA (weeks at birth), BW (50-g increments), gender, BWSDS and SGA calculated and defined

by both the Swedish and Canadian growth references, and severe growth restriction calculated by the Canadian growth reference. First, each risk factor was evaluated separately using logistic regression. For the whole cohort, low GA at birth ($p < 0.001$), low BW ($p < 0.001$), and male gender ($p < 0.05$) were significant risk factors. Neither low $BWSDS_{Sweden}$ nor SGA_{Sweden} were significant risk factors for ROP that will require treatment. However, low $BWSDS_{Canada}$ ($p < 0.001$), SGA_{Canada} ($p < 0.01$), and severe growth restriction ($p < 0.001$) were risk factors. When dividing the infants into GA groups, BWSDS, SGA, and severe growth restriction were significant risk factors for infants born at GA 26–27 weeks independent of whether these were defined according to the Swedish or Canadian growth references (Table 2).

In the next step, multivariable logistic regression analysis was used. Low GA ($p < 0.0001$), male gender ($p < 0.01$ and $p < 0.05$), and the interaction term (BWSDS*GA group) ($p < 0.001$), regardless of BWSDS growth reference, were risk factors for ROP that will require treatment. The multivariable logistic regression analysis was performed with the Swedish as well as the Canadian growth references (Hosmer-Lemeshow test did not indicate any lack of fit for either model, $p_{Swe} = 0.67$, $p_{Can} = 0.53$). Independent of which growth reference was used, BWSDS was less important as a risk factor in infants born at GA < 26 weeks compared with infants born at GA ≥ 26 weeks ($BWSDS_{Sweden}$; OR = 0.80, 95% CI 0.70–0.91 vs OR = 0.56, 95% CI 0.47–0.68 and $BWSDS_{Canada}$; OR = 0.72 95% CI 0.60–0.87 vs OR = 0.41, 95% CI 0.31–0.55) (Table 3 and Figure 3). Consequently, infants born at GA < 26 weeks had reduced odds of requiring treatment by 20–28% for every 1 SD increase in BWSDS compared with infants born at GA ≥ 26 weeks who had a 44–59% reduction for every 1 SD increase in BWSDS.

Table 1. Birth characteristics of infants enrolled in the study by cohort and GA group.

COHORT	No. infants	GA weeks+days median (range)	BW grams median (range)	Swedish reference BWSDS median (range)	SGA BWSDS <-2.0 SDS reference	Canadian reference BWSDS median (range)	SGA BW <10 th percentile Canadian reference	Severe growth restriction BW <3 rd percentile Canadian reference	Male gender % (n)	ROP requiring treatment % (n)
EXPRESS	426	25+4/7 (22+1/7 to 26+6/7)	780 (361-1315)	-0.68 (-5.18 to 3.88)	16.9% (72/426)	0.13 (-2.69 to 2.87)	9.4% (40/426)	2.1% (9/426)	54.0% (230/426)	17.1% (73/426)
North	1772	28+0/7 (22+5/7 to 31+6/7)	1010 (378-2240)	-1.34 (-6.62 to 3.35)	31.6% (560/1772)	-0.20 (-3.27 to 2.87)	13.7% (242/1772)	3.8% (67/1772)	52.5% (931/1772)	9.8% (173/1772)
American	338	28+5/7 (23+1/7 to 31+6/7)	1050 (450-2400)	-1.31 (-5.18 to 4.47)	34.0% (115/338)	-0.11 (-2.58 to 3.07)	13.9% (47/338)	4.7% (16/338)	54.7% (185/338)	4.1% (14/338)
Lund	52	26+1/7 (23+0/7 to 30+5/7)	850 (448-1716)	-0.77 (-5.00 to 0.89)	25.0% (13/52)	-0.01 (-3.07 to 1.30)	7.7% (4/52)	3.8% (2/52)	51.9% (27/52)	17.3% (9/52)
Gothenburg	353	29+4/7 (23+3/7 to 31+6/7)	1290 (425-2210)	-1.04 (-5.59 to 2.50)	22.4% (79/353)	0.02 (-2.88 to 2.47)	11.0% (39/353)	2.3% (8/353)	59.2% (209/353)	7.4% (26/353)
GA GROUP										
GA 22-23	126	23+4/7 (22+1/7 to 23+6/7)	582 (361-925)	-0.46 (-3.27 to 3.88)	5.6% (7/126)	0.13 (-1.56 to 2.87)	4.0% (5/126)	0% (0/126)	52.4% (66/126)	45.2% (57/126)
wk										
GA 24-25	690	25+0/7 (24+0/7 to 25+6/7)	720 (348-1154)	-0.84 (-5.00 to 2.49)	18.0% (124/690)	-0.06 (-3.07 to 2.41)	10.6% (73/690)	2.9% (20/690)	55.2% (381/690)	24.8% (171/690)
wk										
GA 26-27	714	26+6/7 (26+0/7 to 27+6/7)	920 (398-1430)	-1.16 (-5.43 to 2.27)	26.5% (189/714)	-0.03 (-2.87 to 2.28)	11.3% (81/714)	3.8% (27/714)	51.4% (367/714)	8.1% (58/714)
wk										
GA 28-29	695	29+0/7 (28+0/7 to 29+6/7)	1180 (410-2095)	-1.36 (-5.89 to 3.34)	33.1% (230/695)	-0.07 (-3.09 to 2.87)	12.5% (87/695)	3.2% (22/695)	56.0% (389/695)	1.2% (8/695)
wk										
GA 30-31	716	30+6/7 (30+0/7 to 31+6/7)	1422 (378-2400)	-1.67 (-6.62 to 4.47)	40.4% (289/716)	-0.32 (-3.27 to 3.07)	17.6% (126/716)	4.6% (33/716)	52.9% (379/716)	0.1% (1/716)
wk										
Total	2941	27+5/7 (22+1/7 to 31+6/7)	980 (348-2400)	-1.2 (-6.62-4.47)	28.5% (839/2941)	-0.11 (-3.27 to 3.07)	12.6% (372/2941)	3.5% (102/2941)	53.8% (1582/2941)	10.0% (295/2941)

Abbreviations: BW, indicates birth weight; BWSDS, birth weight standard deviation score; GA, gestational age; ROP, retinopathy of prematurity; SGA, small for gestational age.; wk, weeks.
doi:10.1371/journal.pone.0109460.t001




Figure 2. The median BWSDS of infants treated for ROP. The BWSDS was calculated according to the Swedish or Canadian growth reference within each GA group. doi:10.1371/journal.pone.0109460.g002

Discussion

In this study, we established that the impact of low BWSDS and SGA as risk factors for severe ROP requiring treatment is dependent on GA at birth. This result persisted even when we used two different growth charts to calculate BWSDS and define SGA. GA at birth is a strong predictor of ROP and a low BWSDS may enforce the power of this predictor in more mature infants. These findings may help to explain the inconclusive results of previous studies. The risk of developing severe ROP that requires treatment is increased for the most immature infants; growth restriction is less of a risk factor. If born at a more mature age, the preterm infant’s risk is minor for severe ROP unless the infant is born growth restricted. Our new finding that low BWSDS and

SGA increases the risk significantly in more mature infants will be of value when counseling parents regarding their infant’s risk of developing severe ROP and planning for ROP screening. Our findings could improve the ability to identify those more mature infants at greater risk for ROP who may require treatment, and spare mature infants at minor risk at least some of the painful and stressful eye examinations.

In previous studies concerning low BWSDS as a risk factor for ROP, infants were grouped differently. This could explain why the results have been inconclusive [2,3,13,14,16–18]. However, Qui et al. [15] reported that the impact of SGA as a risk factor for severe ROP varies for infants born ≤26, 27–28, 29–30, or 31–32 weeks GA. Consequently, differences among study results concerning low BWSDS as a risk factor for ROP may depend on the infants’ GA at birth. An additional difference in these reports is the degree of ROP investigated, which varied from “any ROP” to “severe ROP”.

Variability among the study results may also arise from the different growth charts used for calculating BWSDS, and in the definition of SGA. In the studies noted above, SGA was defined as a BW deficit of less than the 3rd to below the 10th percentile. In the present study, we chose to use two well-established but different growth references, both of which were developed for preterm infants from GA of 22 weeks, but constructed differently regarding the included infants. We defined SGA as less than –2 SDS of GA-appropriate BW with the Swedish reference, and SGA defined as BW below the 10th percentile with the Canadian reference. We found a significantly lower median BWSDS and higher prevalence of SGA in the cohort when we used the Swedish growth reference to calculate BWSDS compared with results calculated with the Canadian growth reference. This finding is not unexpected since the Swedish reference is based on fetal ultrasound, which is considered to reflect undisturbed intrauterine growth, and the Canadian reference which is based on live and still born preterm infants, regardless cause of preterm birth or death. One must question whether strict cutoffs for prenatal growth restriction, such as SGA, are the preferred choice when estimating an infant’s risk of developing severe ROP.

In univariate logistic regression for the whole cohort, BWSDS_{Sweden} and SGA_{Sweden} were not significant risk factors, whereas BWSDS_{Canada} and SGA_{Canada} were risk factors. These results show that when estimating prenatal growth restriction, the choice of the growth chart reference may affect the results. Subgroup analysis showed that SGA and BWSDS were variable risk factors dependent on GA at birth. Low BWSDS, as well as SGA, regardless of definition, had the same impact. The more mature the infant, the greater the impact of low BWSDS as a risk factor for severe ROP that will require treatment.

In multivariable logistic regression analysis, we confirmed that the odds of requiring treatment for ROP were reduced with higher BWSDS. As we designed an interaction term, the product of relevant BWSDS and GA group, we established that BWSDS (regardless of growth reference) was dependent on GA at birth. Infants born at GA <26 weeks had reduced odds of requiring treatment for ROP by 20–28% for every 1 SD increase in BWSDS compared with infants born at GA ≥26 weeks, who had a 44–59% reduction for every 1 SD increase in BWSDS (BWSDS_{Sweden}; OR = 0.80 vs 0.56 and BWSDS_{Canada}; OR = 0.72 vs 0.41). To our knowledge, no previous study has evaluated BWSDS in preterm infants as a risk factor for severe ROP while taking into account the interaction with GA at birth, and considering different BW deficit references.

The underlying reason for the observed shift in the impact of BWSDS as a risk factor for ROP that will require treatment should

Table 2. Association between infant natal characteristics and ROP that required treatment (analyzed using univariate logistic regression analysis).

Clinical characteristics	Whole cohort	GA groups			
	GA 22–32 wk (n = 2941)	GA 22–23 wk (n = 126)	GA 24–25 wk (n = 690)	GA 26–27 wk (n = 714)	GA 28–29 wk (n = 695)
Variable					
Male gender					
OR	1.30	NS	1.50	NS	NS
95% CI	1.02–1.67*		1.05–2.13*		
GA, wk					
OR	0.47	NS	0.44	NS	NS
95% CI	0.43–0.52***		0.31–0.63***		
BW (50 g increments)					
OR	0.74	NS	0.86	0.79	0.80
95% CI	0.72–0.77***		0.80–0.92***	0.73–0.85***	0.69–0.93**
BWSDS, Swedish reference					
OR	NS	NS	0.86	0.56	0.44
95% CI			0.75–0.99*	0.46–0.69***	0.27–0.73**
SGA, Swedish reference					
OR	NS	NS	NS	3.62	NS
95% CI				2.10–6.25***	
BWSDS, Canadian reference					
OR	0.78	NS	0.70	0.40	0.24
95% CI	0.68–0.89***		0.57–0.86**	0.29–0.54***	0.10–0.54**
SGA, Canadian reference					
OR	1.60	NS	1.80	4.67	12.30
95% CI	1.16–2.20**		1.08–3.01*	2.54–8.57***	2.88–52.41**
Severe growth restriction, Canadian reference					
OR	2.43	–	NS	7.83	21.10
95% CI	1.48–3.99***	–		3.40–18.04***	4.70–94.75***

Abbreviations: BW indicates birth weight; BWSDS, birth weight standard deviation score; GA, gestational age; NS, not significant; OR, odds ratio; ROP, retinopathy of prematurity; SGA, small for gestational age; wk, weeks.

**p* < 0.05,
 ***p* < 0.01,
 ****p* < 0.001.

doi:10.1371/journal.pone.0109460.t002

be discussed. A confounding factor of this finding may be the increasing prevalence of infants born with low BWSDS with increasing GA at birth. Infants born with low BWSDS or SGA have an increased risk for perinatal death, both fetal and neonatal [30–32]. Moreover, when low BWSDS and SGA is associated with additional prematurity, the perinatal mortality rates increase [33]. Stoll et al. [34] suggested that the increased survival rates with increasing GA partly reflect physicians’ attitudes towards providing intensive care, as measured by the frequent use of antenatal corticosteroids as well as the frequency of active resuscitation in the delivery room [34,35]. Consequently, more aggressive lifesaving interventions are initiated for infants born at an older GA, even for severely growth-retarded fetuses. Thus, the increasing impact of low BWSDS as a risk factor for ROP that will require treatment may be a reflection of the increasing number of surviving infants born with low BWSDS with additional GA weeks at birth. Regardless of the reason behind the finding that low BWSDS is a risk factor for ROP depending on GA, the

result remains the same; infants who are born more mature but that are growth restricted should receive adequate attention from the screening ophthalmologist.

Today, most current ROP screening guidelines, which primarily use GA and BW as screening criteria, are vague about the selection of which infants should be screened. Prenatal as well as postnatal growth restriction can be identified by utilizing web-based systems such as WINROP [10,11] and CHOP [36]. By improving the identification of infants at greatest risk for ROP that will require treatment, ophthalmological interventions can focus on those infants at greatest risk, sparing those at minor risk from at least some stressful and painful eye examinations.

In our study, male gender was a significant risk factor for ROP that will require treatment according to univariate logistic regression analysis in the whole cohort (OR = 1.30, 95% CI 1.02–1.47, *p* < 0.05) and for infants born during GA 24–25 week (OR = 1.50, 95% CI 1.16–2.20, *p* < 0.05). In the earliest descriptions of ROP in the 1940s, male preterm infants were described as

Table 3. Association between infant natal characteristics and ROP that required treatment (according to multivariable logistic regression analysis).

Variable	OR	P	95% CI
BWSDS for Infants with GA <26 weeks at birth (Swedish reference)	0.80	0.0007	0.70–0.91
BWSDS for Infants with GA ≥26 weeks at birth (Swedish reference)	0.56	<0.0001	0.47–0.67
GA	0.41	<0.0001	0.35–0.48
Male gender	1.45	0.0085	1.10–1.91
OR variable	OR	p	95% CI
BWSDS for Infants with GA <26 weeks at birth (Canadian reference)	0.72	0.0008	0.60–0.87
BWSDS for Infants with GA ≥26 weeks at birth (Canadian reference)	0.41	<0.0001	0.31–0.55
GA	0.44	<0.0001	0.38–0.51
Male gender	1.32	0.0463	1.00–1.74

Abbreviations: BWSDS indicates birth weight standard deviation score; GA, gestational age; OR, odds ratio; ROP, retinopathy of prematurity.
doi:10.1371/journal.pone.0109460.t003

more frequently affected by ROP than female ones [37]. A few subsequent reports have supported these findings [2,38]. In the multivariable logistic regression analysis, male gender persisted as a risk factor. Whether or not male gender is also a risk factor for severe ROP dependent on GA will require further investigation.

A major strength of this study is that we calculated BWSDS using two different, well-established growth reference charts; one based on undisturbed intrauterine growth, and the other based on live as well as still born preterm infants. Using both reference models, low BWSDS as well as SGA were risk factors for ROP that will require treatment depending on the infants’ immaturity at birth.

Another major strength is the large size of the cohort eligible for assessment, which included 2941 infants from three countries; Canada, Sweden, and the USA. With this constellation of study cohorts, we successfully enrolled almost 700 infants in each pairwise GA group, with the exception of the most preterm group, GA 22–23 weeks.

A limitation of this study is that other established risk factors were not considered when calculating the risk of ROP that will require treatment such as genetic disorders, twin situation, race, and other postnatal morbidities such as days of ventilation, bronchopulmonary dysplasia, septicemia, and necrotizing enterocolitis. Further studies of BWSDS and other postnatal morbidities as risk factors for severe ROP, with special attention to correlations with the infants’ GA at birth, would be of great interest.

In summary, growth restriction at birth, calculated using two differently defined well-established growth references, is an important risk factor for ROP that will require treatment, and was dependent on the infants’ degree of immaturity. ROP screening criteria need to be continually revised according to new findings in order to focus attention on those infants at greatest risk for severe ROP, and to spare infants at reduced risk from at least some of the stressful eye screening examinations.




Figure 3. BWSDS odds ratio for infants for ROP requiring treatment in relation to immaturity. The BWSDS was calculated using the Swedish or Canadian growth chart reference for different GA cut-offs.
doi:10.1371/journal.pone.0109460.g003

Author Contributions

Conceived and designed the experiments: PL CL AH. Performed the experiments: PL CL AH. Analyzed the data: PL EA CL. Contributed

reagents/materials/analysis tools: GH CW LES IHP AH DL AN AH. Wrote the paper: PL CL AH. Reviewed the manuscript and contributed with constructive comment: AK EA IHP GH AN DL LES CW.

References

- Austeng D, Kallen KB, Ewald UW, Jakobsson PG, Holmstrom GE (2009) Incidence of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. *Arch Ophthalmol* 127: 1315–1319.
- Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, et al. (2005) Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. *Pediatrics* 115: 990–996.
- (2010) Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden (EXPRESS). *Acta Paediatr* 99: 978–992.
- Klinger G, Levy I, Sirota L, Boyko V, Lerner-Geva L, et al. (2010) Outcome of early-onset sepsis in a national cohort of very low birth weight infants. *Pediatrics* 125: e736–740.
- Kaempf JW, Kaempf AJ, Wu Y, Stawarz M, Niemeyer J, et al. (2011) Hyperglycemia, insulin and slower growth velocity may increase the risk of retinopathy of prematurity. *J Perinatol* 31: 251–257.
- Fortes Filho JB, Eckert GU, Valiatti FB, Dos Santos PG, da Costa MC, et al. (2010) The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of prematurity (ROP). *Graefes Arch Clin Exp Ophthalmol* 248: 893–900.
- Holmstrom G, Broberger U, Thomassen P (1998) Neonatal risk factors for retinopathy of prematurity—a population-based study. *Acta Ophthalmol Scand* 76: 204–207.
- Allegaert K, Vanhole C, Casteels I, Naulaers G, Debeer A, et al. (2003) Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity. *Journal of Aapos* 7: 34–37.
- Binenbaum G, Ying GS, Quinn GE, Dreiseitl S, Karp K, et al. (2011) A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain. *Pediatrics* 127: e607–614.
- Hellstrom A, Hard AL, Engstrom E, Niklasson A, Andersson E, et al. (2009) Early Weight Gain Predicts Retinopathy in Preterm Infants: New, Simple, Efficient Approach to Screening. *Pediatrics* 123: E638–E645.
- Loqvist C, Hansen-Pupp I, Andersson E, Holm K, Smith LEH, et al. (2009) Validation of a New Retinopathy of Prematurity Screening Method Monitoring Longitudinal Postnatal Weight and Insulinlike Growth Factor I. *Archives of Ophthalmology* 127: 622–627.
- Wallace DK, Kylstra JA, Phillips SJ, Hall JG (2000) Poor postnatal weight gain: A risk factor for severe retinopathy of prematurity. *Journal of Aapos* 4: 343–347.
- Bardin C, Zelkowitz P, Papageorgiou A (1997) Outcome of small-for-gestational age and appropriate-for-gestational age infants born before 27 weeks of gestation. *Pediatrics* 100: E4.
- Zaw W, Gagnon R, da Silva O (2003) The risks of adverse neonatal outcome among preterm small for gestational age infants according to neonatal versus fetal growth standards. *Pediatrics* 111: 1273–1277.
- Qiu X, Lodha A, Shah PS, Sankaran K, Seshia MM, et al. (2012) Neonatal outcomes of small for gestational age preterm infants in Canada. *Am J Perinatol* 29: 87–94.
- Allegaert K, de Coen K, Devlieger H (2004) Threshold retinopathy at threshold of viability: the EpiBel study. *Br J Ophthalmol* 88: 239–242.
- Woo SJ, Park KH, Ahn J, Oh KJ, Lee SY, et al. (2011) A co-twin study of the relative effect of birth weight and gestational age on retinopathy of prematurity. *Eye (Lond)* 25: 1478–1483.
- Fortes Filho JB, Valiatti FB, Eckert GU, Costa MC, Silveira RC, et al. (2009) Is being small for gestational age a risk factor for retinopathy of prematurity? A study with 345 very low birth weight preterm infants. *J Pediatr (Rio J)* 85: 48–54.
- Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, et al. (1996) Intrauterine growth curves based on ultrasonically estimated foetal weights. *Acta Paediatr* 85: 843–848.
- Niklasson A, Albertsson-Wikland K (2008) Continuous growth reference from 24(th) week of gestation to 24 months by gender. *Bmc Pediatrics* 8.
- Roberts CL, Lancaster PA (1999) Australian national birthweight percentiles by gestational age. *Med J Aust* 170: 114–118.
- Usher R, McLean F (1969) Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. *J Pediatr* 74: 901–910.
- Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, et al. (2001) A new and improved population-based Canadian reference for birth weight for gestational age. *Pediatrics* 108: E35.
- Lundgren P, Stoltz Sjostrom E, Domellof M, Kallen K, Holmstrom G, et al. (2013) WINROP identifies severe retinopathy of prematurity at an early stage in a nation-based cohort of extremely preterm infants. *PLoS One* 8: e73256.
- Wu C, Lofqvist C, Smith LEH, VanderVeen DK, Hellstrom A, et al. (2012) Importance of Early Postnatal Weight Gain for Normal Retinal Angiogenesis in Very Preterm Infants A Multicenter Study Analyzing Weight Velocity Deviations for the Prediction of Retinopathy of Prematurity. *Archives of Ophthalmology* 130: 992–999.
- Wu C, VanderVeen DK, Hellstrom A, Lofqvist C, Smith LEH (2010) Longitudinal Postnatal Weight Measurements for the Prediction of Retinopathy of Prematurity. *Archives of Ophthalmology* 128: 443–447.
- Gole GA, Ells AL, Katz X, Holmstrom G, Fielder AR, et al. (2005) The international classification of retinopathy of prematurity revisited. *Archives of Ophthalmology* 123: 991–999.
- Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, et al. (2003) Revised indications for the treatment of retinopathy of prematurity - Results of the early treatment for retinopathy of prematurity randomized trial. *Archives of Ophthalmology* 121: 1684–1696.
- Hosmer DW, Lemeshow S (2000) *Applied Logistic Regression*. New York: John Wiley and Sons, Inc.
- Piper JM, Xenakis EMJ, McFarland M, Elliott BD, Berkus MD, et al. (1996) Do growth-retarded premature infants have different rates of perinatal morbidity and mortality than appropriately grown infants? Reply. *Obstetrics and Gynecology* 87: 1064–1064.
- McIntire DD, Bloom SL, Casey BM, Leveno KJ (1999) Birth weight in relation to morbidity and mortality among newborn infants. *New England Journal of Medicine* 340: 1234–1238.
- Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A (2013) Maternal and fetal risk factors for stillbirth: population based study. *BMJ* 346: f108.
- Kamoi VM, Dorling JS, Manktelow BN, Draper ES, Field DJ (2006) Extremely growth-retarded infants: Is there a viability centile? *Pediatrics* 118: 758–763.
- Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, et al. (2010) Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network. *Pediatrics* 126: 443–456.
- Smith PB, Ambalavanan N, Li L, Cotten CM, Laughon M, et al. (2012) Approach to Infants Born at 22 to 24 Weeks' Gestation: Relationship to Outcomes of More-Mature Infants. *Pediatrics* 129: E1508–E1516.
- Binenbaum G, Ying GS, Quinn GE, Huang J, Dreiseitl S, et al. (2012) The CHOP Postnatal Weight Gain, Birth Weight, and Gestational Age Retinopathy of Prematurity Risk Model. *Arch Ophthalmol* 130: 1560–1565.
- Kinsey VE, Zacharias L (1949) Retrolental fibroplasia; incidence in different localities in recent years and a correlation of the incidence with treatment given the infants. *J Am Med Assoc* 139: 572–578.
- Nodgaard H, Andreassen H, Hansen H, Sorensen HT (1996) Risk factors associated with retinopathy of prematurity (ROP) in northern Jutland, Denmark 1990–1993. *Acta Ophthalmol Scand* 74: 306–310.